Loymaxi Joint

Loymaxi Joint is a combination therapeutic product marketed by Lloyd Healthcare, an Indian pharmaceutical company, as part of its orthopedic and musculoskeletal portfolio. It is primarily indicated for the management of osteoarthritis and the relief of joint pain and stiffness. The formulation typically combines **Glucosamine Sulfate**, **Diacerein**, and **Methylsulfonylmethane (MSM)**. Glucosamine serves as a fundamental building block for the synthesis of glycosaminoglycans and proteoglycans in the cartilage matrix, supporting structural repair. Diacerein is a slow-acting drug that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1β), which is a key mediator in the pathogenesis of osteoarthritis, leading to reduced cartilage degradation and synovial inflammation. MSM provides a source of organic sulfur, which exerts anti-inflammatory and antioxidant effects, helping to alleviate joint swelling and oxidative stress. Together, these components aim to improve joint mobility and slow the progression of degenerative joint disease.

Brand names

Loymaxi Joint

Other names

Loymaxi Joint-Lloyd-orthopedic